{"id":"W4306319940","doi":"10.1016/j.htct.2022.09.415","title":"A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3","year":2022,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Multiple myeloma; Cohort; Refractory (planetary science); Antibody; Oncology; Immunology; Cancer; Immunotherapy; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000722335,0.0003236114,0.0008324907,0.0004838299,0.0002799119,0.00001528514,0.0001760581,0.0002321457,0.001170015],"category_scores_gemma":[0.00002311004,0.000276304,0.0001788019,0.00047885,0.0002151009,0.0001034364,0.00003442503,0.0005740193,0.000002703884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007954668,"about_ca_system_score_gemma":0.0002062657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001079479,"about_ca_topic_score_gemma":0.00008941552,"domain_scores_codex":[0.9969357,0.0004269632,0.0008946616,0.0006767779,0.0005942075,0.0004716989],"domain_scores_gemma":[0.9985909,0.0004001021,0.0002409435,0.0004584503,0.0001575616,0.0001520543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7412404,0.0102508,0.002261509,0.00019313,0.0000594563,0.0000825988,0.002616507,0.000005099991,0.2098777,0.00003608907,0.0003690477,0.03300761],"study_design_scores_gemma":[0.8066518,0.04128265,0.00389966,0.00008488343,0.0000500708,0.00007864837,0.001018445,0.0005647356,0.09493297,0.00004540429,0.05096152,0.0004292042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917379,0.0008981949,0.0003467184,0.0003895461,0.0002871912,0.004536392,0.0002897504,0.00004602116,0.001468298],"genre_scores_gemma":[0.9921859,0.00529249,0.0003530067,0.0001728656,0.00006454025,0.0002506954,0.000976284,0.00006809754,0.0006361131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1149447,"threshold_uncertainty_score":0.9999689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02203625195843619,"score_gpt":0.307113675771095,"score_spread":0.2850774238126588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}